Preferred Label : multiple sclerosis, relapsing-remitting;

MeSH definition : The most common clinical variant of MULTIPLE SCLEROSIS, characterized by recurrent acute exacerbations of neurologic dysfunction followed by partial or complete recovery. Common clinical manifestations include loss of visual (see OPTIC NEURITIS), motor, sensory, or bladder function. Acute episodes of demyelination may occur at any site in the central nervous system, and commonly involve the optic nerves, spinal cord, brain stem, and cerebellum. (Adams et al., Principles of Neurology, 6th ed, pp903-914);

MeSH synonym : relapsing remitting multiple sclerosis; multiple sclerosis, remitting-relapsing; remitting relapsing multiple sclerosis; remitting-relapsing multiple sclerosis; relapsing-remitting multiple sclerosis; multiple sclerosis, relapsing remitting;

Related MeSH term : multiple sclerosis, acute relapsing; Acute Relapsing Multiple Sclerosis;

MeSH annotation : DF: MS RELAPSING REMITTING;

Details


Main resources

You can consult :

The most common clinical variant of MULTIPLE SCLEROSIS, characterized by recurrent acute exacerbations of neurologic dysfunction followed by partial or complete recovery. Common clinical manifestations include loss of visual (see OPTIC NEURITIS), motor, sensory, or bladder function. Acute episodes of demyelination may occur at any site in the central nervous system, and commonly involve the optic nerves, spinal cord, brain stem, and cerebellum. (Adams et al., Principles of Neurology, 6th ed, pp903-914)

https://www.cochrane.org/fr/CD011381/MS_quels-sont-les-benefices-et-les-risques-des-medicaments-agissant-sur-le-systeme-immunitaire-pour
2024
false
false
false
France
United Kingdom
review of literature
french abstract
Immunomodulators
immunosuppressive agents
multiple sclerosis, nos
Network Meta-Analysis
immunomodulators
Multiple sclerosis
multiple sclerosis, relapsing-remitting
multiple sclerosis
immunologic factors

---
https://www.has-sante.fr/portail/jcms/c_2913088/fr/gilenya
2019
false
true
false
false
France
administration, oral
child
adolescent
treatment outcome
fingolimod
immunosuppressive agents
multiple sclerosis, relapsing-remitting
insurance, health, reimbursement
fingolimod
Fingolimod Hydrochloride
Fingolimod Hydrochloride
evaluation of the transparency committee
Fingolimod Hydrochloride

---
https://www.has-sante.fr/jcms/p_3067012/fr/medicaments-utilises-dans-les-formes-tres-actives-de-sclerose-en-plaques-recurrente
2019
false
true
false
false
France
guidelines for drug use
immunosuppressive agents
Fingolimod Hydrochloride
ocrelizumab
mitoxantrone
Natalizumab
multiple sclerosis, relapsing-remitting
antibodies, monoclonal, humanized

---
https://www.cochrane.org/fr/CD009371/le-fingolimod-pour-la-sclerose-en-plaques-recurrente-remittente
2016
false
false
false
false
France
United Kingdom
Fingolimod Hydrochloride
Fingolimod Hydrochloride
review of literature
french abstract
fingolimod
multiple sclerosis, relapsing-remitting
Fingolimod Hydrochloride

---
https://medicalforum.ch/fr/detail/doi/fms.2014.02124/
2014
false
false
false
Switzerland
French
journal article
multiple sclerosis, relapsing-remitting
algorithms

---
https://www.cochrane.org/fr/CD009333/une-comparaison-de-lefficacite-et-de-la-securite-des-deux-traitements-les-plus-courants-pour-les-personnes-atteintes-de-sclerose-en-plaques-sep
2014
false
false
false
France
United Kingdom
French
meta-analysis
multiple sclerosis
interferon-beta
treatment outcome
multiple sclerosis, relapsing-remitting
french abstract
comparative study
Glatiramer Acetate

---
http://www.cochrane.org/fr/CD010242/le-mycophenolate-mofetil-pour-la-sclerose-en-plaques-recurrente-remittente
false
false
false
France
United Kingdom
review of literature
french abstract
immunosuppressive agents
mycophenolic acid
treatment outcome
multiple sclerosis, relapsing-remitting
mycophenolic acid

---
http://www.cochrane.org/fr/CD006921
2012
France
United Kingdom
French
french abstract
meta-analysis
multiple sclerosis, relapsing-remitting
recurrence
glucocorticoids
administration, intravenous
administration, oral
treatment outcome
comparative study
anti-inflammatory agents
Adrenocortical steroid therapy
Glucocorticoid therapy
corticosteroid therapy

---
http://www.cochrane.org/fr/CD008127
http://www.cochrane.org/fr/CD008127/le-daclizumab-zenapax-est-un-medicament-immunosuppresseur-dont-lefficacite-chez-les-patients-atteints-de-sclerose-en-plaques-sep-merite-quelque-attention
2012
false
true
false
United Kingdom
France
immunosuppressive agents
immunosuppressive agents
review of literature
french abstract
multiple sclerosis, relapsing-remitting
Daclizumab
Daclizumab

---
http://www.john-libbey-eurotext.fr/fr/revues/medecine/nro/e-docs/00/04/56/F8/resume.phtml
2010
false
France
French
Glatiramer Acetate
immunologic factors
glatiramer acetate
multiple sclerosis, relapsing-remitting
interferon-beta
interferon beta-1a
interferon beta-1b
disabled persons
treatment outcome
journal article

---
Nous contacter.
16/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.